Rapid Development of Complex Generics: Achieving in vitro Q3 bioequivalence through the application of physicochemical characterization methods

Log in to watch this webinar

Not registered yet? Konto erstellen
00:00:00 Welcome
00:00:05 Introduction
00:02:05 Rapid Development of Complex GenericsAchieving in vitro Q3 bioequivalence through the applicationof physicochemical characterization methods
00:02:15 Complex generic products
00:04:23 Complex generic products
00:05:57 Q3 bioequivalence requirements
00:07:38 Untitled
00:08:54 Proposed deformulation workflow
00:11:00 Proposed deformulation workflow
00:12:05 Solutions for pharmaceutical Development & Manufacture
00:13:25 Nasal sprays: IVBE guidance
00:14:59 Nasal Sprays
00:15:58 Nasal sprays: droplet sizing
00:17:33 Nasal sprays: droplet sizing
00:18:57 Nasal sprays: droplet sizing
00:21:23 Nasal sprays: droplet sizing
00:22:19 Nasal sprays: API particle size
00:22:57 Analytical imaging: mdrS
00:23:41 Nasal sprays: API particle size
00:24:55 Nasal sprays: API particle size
00:25:31 Nasal sprays: API particle size
00:26:05 Nasal sprays: API particle size
00:26:40 Nasal sprays
00:28:03 Topical creams: IVBE guidance
00:29:02 Topical Creams
00:29:44 Topical creams
00:30:34 Topical creams
00:31:47 Topical creams
00:32:27 Topical creams
00:33:26 Topical creams
00:33:58 Q3 bioequivalence requirements
00:34:52 Solutions for pharmaceutical development & manufacture
00:35:14 Q&A
00:41:28 Thank you for attention

In the face of increasing pressure on health care access and costs, regulators such as the US FDA are actively seeking ways to enable the rapid development and launch of new generic medicines. Within this, there has been significant focus on complex products, such as OINDP (Orally Inhaled and Nasal Drug Products) and topical creams, where the delivery method and site of action makes bioequivalence assessments difficult using traditional in vivo approaches. As a result, many off-patent complex drug products are not subject to generic competition. The US FDA has therefore committed to providing improved scientific and regulatory clarity with respect to complex generic drug approvals, leading to the publication of product-specific guidance documents which outline the requirements for assessing in vitro bioequivalence by considering physicochemical (Q3) equivalence. 

This webinar will consider the workflows associated with evaluation of physicochemical (Q3) bioequivalence with reference to the measurement solutions offered by Malvern Panalytical. In this webinar, we will introduce a toolbox of physicochemical analysis techniques which are increasingly being employed to assist with the evaluation of physicochemical (Q3) bioequivalence for complex generic drug products in vitro. Example case studies will be shared, including data on topical cream and nasal spray formulations.

Find out more about our solutions in our Pharmaceuticals section of our website.